All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 14 January 2019, zanubrutinib (BGB-3111), an investigational Bruton’s tyrosine kinase (BTK) inhibitor, was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior line of therapy. Additionally, zanubrutinib has been granted Fast Track designation for the treatment of patients with Waldenström macroglobulinemia.
The Breakthrough Therapy Designation granted by the FDA was based on the positive results obtained from the single-arm, open-label, multi-center phase II trial (NCT03206970) assessing the efficacy and safety of BGB-3111, in patients with MCL who had received one to four previous lines of therapy.
The phase II study demonstrated an overall response rate in relapsed/refractory patients following treatment with BGB-3111 was 88.9%, according to investigator assessment, which suggests responses to therapy were durable. Furthermore, the median duration of response was 16.2 months and median progression-free survival for relapsed/refractory patients was 18.0 months.
According to the drug manufacturers, the third Breakthrough Therapy Designation granted for BGB-3111, “underscores the potential of zanubrutinib as a meaningful treatment for patients with MCL who have received at least one prior therapy.”
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox